BSE Live
Aug 13, 16:01Prev. Close
15.70
Open Price
14.86
Bid Price (Qty.)
15.60 (10)
Offer Price (Qty.)
15.80 (200)
NSE Live
Aug 13, 15:46Prev. Close
15.76
Open Price
15.16
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Ind-Swift (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 18 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 515.23 | 492.53 | 398.89 | 391.30 | 270.57 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 515.23 | 492.53 | 398.89 | 391.30 | 270.57 | |
| Total Operating Revenues | 515.23 | 502.25 | 410.96 | 397.71 | 270.57 | |
| Other Income | 47.62 | 57.99 | 11.85 | 23.55 | 10.16 | |
| Total Revenue | 562.85 | 560.24 | 422.81 | 421.26 | 280.73 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 224.56 | 206.50 | 194.97 | 192.28 | 125.35 | |
| Purchase Of Stock-In Trade | 45.98 | 44.83 | 38.50 | 20.15 | 36.89 | |
| Operating And Direct Expenses | 0.00 | 25.33 | 23.85 | 25.07 | 0.00 | |
| Changes In Inventories Of FGWIP And Stock In Trade | -10.36 | 29.85 | -15.43 | -1.41 | -8.09 | |
| Employee Benefit Expenses | 91.81 | 78.32 | 69.15 | 63.15 | 48.27 | |
| Finance Costs | 39.16 | 62.94 | 59.76 | 57.16 | 7.05 | |
| Depreciation And Amortisation Expenses | 23.50 | 27.11 | 28.67 | 32.07 | 34.63 | |
| Other Expenses | 140.26 | 68.92 | 57.89 | 53.12 | 61.85 | |
| Total Expenses | 554.91 | 543.78 | 457.35 | 441.60 | 305.96 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 7.94 | 16.46 | -34.54 | -20.34 | -25.23 | |
| Exceptional Items | 279.97 | 0.00 | 60.58 | 0.73 | -28.15 | |
| Profit/Loss Before Tax | 287.91 | 16.46 | 26.04 | -19.60 | -53.38 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 4.46 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Less: MAT Credit Entitlement | 0.00 | -2.27 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 4.46 | 2.23 | 0.00 | 0.42 | 0.75 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 283.45 | 14.23 | 26.04 | -20.02 | -54.13 | |
| Profit/Loss From Continuing Operations | 283.45 | 14.23 | 26.04 | -20.02 | -54.13 | |
| Profit/Loss For The Period | 283.45 | 14.23 | 26.04 | -20.02 | -54.13 | |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Consolidated Profit/Loss After MI And Associates | 283.45 | 14.23 | 26.04 | -20.02 | -50.43 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 52.00 | 3.00 | 5.00 | -4.00 | -9.00 | |
| Diluted EPS (Rs.) | 52.00 | 3.00 | 5.00 | -4.00 | -9.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
30.06.2025
Ind-Swift Standalone March 2025 Net Sales at Rs 144.90 crore, up 7.15% Y-o-Y
28.02.2025
Ind-Swift Consolidated December 2024 Net Sales at Rs 120.13 crore, up 17.13% Y-o-Y
17.02.2025
Ind-Swift Standalone December 2024 Net Sales at Rs 120.13 crore, up 17.13% Y-o-Y
28.11.2024
Ind-Swift Consolidated September 2024 Net Sales at Rs 136.35 crore, up 17.62% Y-o-Y
30.06.2025
Ind-Swift Standalone March 2025 Net Sales at Rs 144.90 crore, up 7.15% Y-o-Y
28.02.2025
Ind-Swift Consolidated December 2024 Net Sales at Rs 120.13 crore, up 17.13% Y-o-Y
17.02.2025
Ind-Swift Standalone December 2024 Net Sales at Rs 120.13 crore, up 17.13% Y-o-Y
28.11.2024
Ind-Swift Consolidated September 2024 Net Sales at Rs 136.35 crore, up 17.62% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth